Article
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Amino acids - 1 Feb 2016
Meng Xuli, Li Yongfeng, Tang Hongchao, Mao Weimin, Yang Hongjian, Wang Xiaojia, Ding Xianfeng, Xie Shangnao
Abstract excerpt
The gatekeeper T798M mutation in HER2 kinase domain has been observed to considerably shift drug sensitivity to HER2 in breast cancer therapy. Here, drug response of clinical tyrosine kinase inhibitors (TKIs) to the mutation was profiled using a synthetic biology protocol. It was found that TKIs can be grouped into three classes in terms of their response behavior to T798M mutation: class I inhibitors exhibit...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.